Cancer classification and pathway discovery using non-negative matrix
  factorization by Zeng, Zexian et al.
 Cancer classification and pathway discovery using 
non-negative matrix factorization   
                                          
Zexian Zeng  
Preventive Medicine 
Northwestern University 
Feinberg School of Medicine 
Chicago, IL, USA 
zexian.zeng@northwestern.edu 
Andy Vo 
Developmental Biology and 
Regenerative Medicine 
University of Chicago 
Chicago, IL, USA 
ahvo@uchicago.edu 
Chengsheng Mao 
Preventive Medicine 
Northwestern University 
Feinberg School of Medicine 
Chicago, IL, USA 
chengsheng.mao@northwester
n.edu 
Susan E Clare* 
Surgery 
Northwestern University 
Feinberg School of Medicine 
Chicago, IL, USA 
susan.clare@northwestern.edu 
Seema A Khan* 
Surgery 
Northwestern University 
Feinberg School of Medicine 
Chicago, IL, USA 
s-khan2@northwestern.edu 
Yuan Luo* 
Preventive Medicine 
Northwestern University 
Feinberg School of Medicine 
Chicago, IL, USA 
yuan.luo@northwestern.edu 
 
 
 
 
 
 
Abstract— Extracting genetic information from a full 
range of sequencing data is important for understanding 
diseases. We propose a novel method to effectively explore 
the landscape of genetic mutations and aggregate them to 
predict cancer type. We used multinomial logistic 
regression, nonsmooth non-negative matrix factorization 
(nsNMF), and support vector machine (SVM) to utilize the 
full range of sequencing data, aiming at better aggregating 
genetic mutations and improving their power in predicting 
cancer types. Specifically, we introduced a classifier to 
distinguish cancer types using somatic mutations obtained 
from whole-exome sequencing data. Mutations were 
identified from multiple cancers and scored using SIFT, 
PP2, and CADD, and grouped at the individual gene level. 
The nsNMF was then applied to reduce dimensionality and 
to obtain coefficient and basis matrices. A feature matrix 
was derived from the obtained matrices to train a classifier 
for cancer type classification with the SVM model. We have 
demonstrated that the classifier was able to distinguish the 
cancer types with reasonable accuracy. In five-fold cross-
validations using mutation counts as features, the average 
prediction accuracy was 77.1% (SEM=0.1%), significantly 
outperforming baselines and outperforming models using 
mutation scores as features. Using the factor matrices 
derived from the nsNMF, we identified multiple genes and 
pathways that are significantly associated with each cancer 
type. This study presents a generic and complete pipeline to 
study the associations between somatic mutations and 
cancers. The discovered genes and pathways associated 
with each cancer type can lead to biological insights. The 
proposed method can be adapted to other studies for disease 
classification and pathway discovery. 
Keywords— Non-negative matrix factorization; Cancer; 
Classification; Whole-exome sequencing; Somatic mutation; 
Pathway 
I. INTRODUCTION  
Understanding the association between genetics and disease is 
important for understanding the underlying pathophysiology, 
planning treatment, and predicting prognostic outcomes. In 
cancer, many molecular and genomic studies have identified 
somatic mutations within numerous genes associated with 
cancer initiation, progression, and treatment responses [1-3]. 
More recently, the idea of personalized medicine is becoming 
increasingly popular where genetic profiles of tumors can be 
used to guide clinical decisions such as treatment options and 
preventive measures [4]. The development of massively 
parallel, high throughput DNA sequencing technology has 
enabled the cataloging of somatic mutations in cancer, making 
personalized medicine increasingly achievable.  
The majority of genome-wide sequencing studies have focused 
on the identification of individual driver genes [5].  However, 
driver mutations are often highly heterogeneous between 
cancer genomes, even within the same type [6]. Furthermore, 
studies have observed cancer to be highly complex, often 
resulting from multiple interacting mutations and related 
pathways [7, 8]. While many methods attempt to address the 
complex mutational heterogeneity in disease, it still remains 
challenging due to limited study-power and lack of complete 
knowledge regarding gene and pathway interaction, 
particularly in cancer [9-13]. Individually, genes can show a 
small contribution to disease phenotype but can have a 
significant effect when analyzed together [14]. Thus, it is 
important to consider methods that can encompass the full 
scope of genes. When genes and mutations are studied together, 
novel biological interactions and pathways can be identified, 
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 and the information can further provide us with biological and 
clinical insights.  
II. RELATED WORK 
Numerous studies have been performed for cancer 
classification using information from somatic mutations. Early 
work mainly relied on gene expression profiles for cancer type 
classification [15-17]. PAM50 is a well-known panel for cancer 
subtype classification, which utilizes 50 gene expression levels 
and classifies breast cancer mainly into four subtypes. Recently, 
DNA methylation profiles have been explored [18, 19] for 
cancer type classification. The majority of studies involving 
DNA mutations have used mutations as individual variables. 
Soh et al. [20] used somatic mutations derived from 100 
representative genes to distinguish cancer types and the results 
concluded that using somatic point mutations alone as 
individual variables was not sufficient to classify cancer types. 
Despite the fact that mutations in many genes have been 
identified in cancer, it is not yet understood how these genes 
cumulatively interact in the development and progression of 
cancer.  
Cancer is thought to occur as a consequence of progressive 
mutational accumulation over time. It has been a challenge to 
study these mutations and their interactions together due to 
large-scale complexity. As a result, many groups utilize feature 
selection as a method for removing irrelevant and redundant 
information to deal with the complexity problems. Vector 
Quantization (VQ) [21] and Principle Component Analysis 
(PCA) [22] have been widely used for feature selection. Recent 
attention has been drawn to non-negative matrix factorization 
(NMF). In a face recognition study, Lee et al. presented that 
NMF outperformed VQ and PCA for feature recognition [23]. 
In addition, the non-negative constraint of NMF is important 
because non-negativity is more realistic, easier to interpret, and 
prevalent in real world applications. NMF has been used for a 
wide range of applications such as document clustering [24], 
text mining [24, 25], biological data subgrouping [26], time 
series analysis [27, 28], blind source separation [29], and signal 
processing [30]. In particular, NMF has been applied to disease 
subtype studies using gene expression data [26, 31] and 
sequencing data [32-34]. However, NMF has not been used as 
a cancer classifier using somatic mutations obtained from 
whole-exome sequencing data.  
In our study, we proposed a novel method of using NMF to 
reduce the genetic complexity behind cancer development 
using somatic mutation information. We hypothesize that the 
mutations identified individually or in combination will be 
significantly different between cancers that directly affect 
processes involved with oncogenesis. Using NMF, we hope to 
identify latent groups of genes that link to different cancers, 
aiming at improving the feature selection of genetic mutations 
by reducing false negatives and at the same time amplify the 
effects of true positives, thus to improve their statistical power 
in predicting cancer types.  
In this study, NMF and support vector machine (SVM) [35] 
methods were used to study somatic mutations for multiple 
cancers. As a pilot study, four cancers were used for subsequent 
studies, including Glioblastoma Multiforme (GBM), Breast 
invasive carcinoma (BRCA), Lung Squamous Cell Carcinoma 
(LUSC), and Prostate Adenocarcinoma (PRAD). NMF was 
applied to discover latent factors from the somatic mutations 
within a group of selected genes. The latent factors discovered 
from NMF were then used to derive features to train an SVM 
as the classifier for the four different cancer types. The NMF-
SVM combination was rigorously evaluated and compared to 
different baselines. Association studies were performed 
between the factor matrices derived from NMF and cancer type 
using penalized logistical regressions. Major factors that are 
associated with each cancer type were investigated, and 
significant genes were identified. Using the identified gene sets, 
enrichment studies were performed using Metascape [36], and 
the significant GO terms were reported. The details of the study 
are reported below.  
III. METHODOLOGY 
A. Mutation Profiles 
Somatic mutation from four cancers including Glioblastoma 
Multiforme (GBM), Breast invasive carcinoma (BRCA), Lung 
Squamous Cell Carcinoma (LUSC), and Prostate 
Adenocarcinoma (PRAD) were identified from 2431 tumors. 
The number of samples and mutations varied between cancers 
as shown in Figure 1. The mutations were functionally 
annotated by SnpEFF[37] and ANNOVAR [38]. In this study 
cohort, 245,888 mutations were predicted to have moderate 
effects by SnpEFF, and 57,319 mutations were predicted to 
have high effects. Moderate effects are defined as missense 
mutations and high effects are defined as nonsense mutations. 
Each mutation was functionally scored using SIFT [25], 
PolyPhen2 (PP2) [26], and CADD [24] scores as obtained by 
ANNOVAR. In genes containing multiple mutations, SIFT, 
PP2, and CADD scores, as well as mutational frequency were 
collapsed and studied as a single variable separately, which is 
known as gene burden [39]. These mutation frequency, SIFT, 
PP2, and CADD scores measure the damage levels of genes 
from various perspectives. To illustrate the methods used in this 
study, we have summarized the workflow in Figure 2.  
B. Gene Preselection 
Prior to modeling, we preselected a group of representative 
genes in cancer to achieve a more balanced sample feature ratio 
and reduce noise. Somatic mutations from 8198 tumors of 18 
cancers were retrieved from The Cancer Genome Atlas 
(TCGA) database. Only mutations in protein-coding genes 
were used. The number of mutations or collapsed scores in each 
gene was used as the input variable while the cancer type was 
used as the output variable. Multinomial logistic regression was 
fit, and a P-value that yields the null hypothesis of 
corresponding coefficient being zero was used as an indicator 
for the pre-selection. The selection criterion for this initial 
screening was set as P-value less than or equal to a cutoff. In 
order to reduce noise and to prevent the model from being 
overfitted, we tested the model using multiple cutoff thresholds  
 
  
Figure 1: Sample size in each cancer type. The somatic moderate are the mutations that have moderate effect predicted by SnpEFF. The somatic high are ones 
predicted to have high effects. The numbers in parentheses are 95% confidence intervals.  
 
 
of 0.05, 0.1, 0.2, 0.5,  and 1. We compared the results derived 
from each threshold and selected the most reasonable cutoff 
regarding prediction accuracy and number of features. 
C. Applying NMF to Discover Latent Factors of Somantic 
Mutations 
Genes passing the selection threshold were used as input for 
NMF. In the study, we assume that there are N subjects and M 
selected genes. The data was represented separately by a matrix 
𝐴𝑆𝑐𝑜𝑟𝑒  of size 𝑁 × 𝑀 . The columns of 𝐴𝑆𝑐𝑜𝑟𝑒  represents the 
collapsed score of the 𝑀 genes in the 𝑁 subjects. The matrix 
𝐴𝑆𝑐𝑜𝑟𝑒  was then factorized by NMF. The purpose of this study 
was to find a set of representative features that are likely to 
distinguish cancer types.  
To perform 𝑁𝑀𝐹, the matrix 𝐴𝑆𝑐𝑜𝑟𝑒  was factored into two low-
rank matrices 𝑊  and 𝐻 . Mathematically, 𝐴𝑆𝑐𝑜𝑟𝑒  is 
approximated by:   
 
𝐴𝑆𝑐𝑜𝑟𝑒 ≈ 𝑊 × 𝐻            (1) 
 
Matrix 𝐴𝑆𝑐𝑜𝑟𝑒  is the approximate linear combinations of the 
column vectors in matrix 𝑊 and the coefficients supplied by 
columns in matrix 𝐻. Matrix 𝑊 has size 𝑁 × 𝐾, with each of 
the 𝐾 columns representing a group of weighted genes and 
𝑤𝑖𝑗 corresponding to the weight of gene 𝑖 in group 𝑗.  Matrix 
𝐻 has size 𝐾 × 𝑁, where each of the 𝑁 columns denotes 
 
 
Figure 2： Workflow of the study. Orange boxes are the data or processes; green boxes are the tools used; blue boxes are the results of the study.  
 the feature coefficients for each subject. Entry ℎ𝑖𝑗 is the value  
of feature 𝑖 in sample 𝑗.  
The decomposition is achieved by iteratively updating the 
matrix 𝑊 and 𝐻 to minimize a divergence objective [23, 40]. 
Specifically, for the purpose of sparseness, we used non-smooth 
Nonnegative Matrix Factorization (nsNMF) for feature 
selection [41]. Each experiment was repeated ten times to 
address the local optima problem. Then, the derived features 
were applied to train a classifier for cancer type. 
D. Classifier Training 
Matrix 𝐻 has size 𝐾 × 𝑁, where each of the 𝑁 columns denotes 
the feature coefficients for the corresponding subject. Each 
sample is placed into the group corresponding to the highest 
feature coefficient. In this study, to retain the information from 
both matrices, a new matrix 𝐹 was generated by multiplying 
matrix 𝐴𝑆𝑐𝑜𝑟𝑒 with matrix 𝑊. Specifically, an entry in matrix 𝐹 
can be computed as: 
𝑓𝑖𝑗 = ∑ 𝐴𝑖𝑥 ∗ 𝑊𝑥𝑗
𝑛
𝑥=1            (2) 
 
Matrix F has size 𝑁 × 𝐾, 𝑁 denotes the number of subjects, 𝐾 
denotes the number of factors and is a given input. Each of the 
𝐾 columns represents the accumulative effect of 𝑀 genes for 
each subject. Since 𝐴𝑆𝑐𝑜𝑟𝑒 ≈ 𝑊 × 𝐻 , matrix 𝐹  can be 
approximated by a kernel matrix 𝑊 × 𝐻 × 𝑊 . In this way, 
matrix 𝐹  retains the information from both matrix 𝑊  and 
matrix 𝐻. Subsequently, columns in matrix 𝐹 can be used as 
training features to train the classifier. Support vector machine 
(SVM) was used for the training, each column corresponds to 
one predictor in the model. The Radial Basis Function (RBF) 
kernel is used, with parameters of gamma and C set to default. 
This trained SVM model was then used as a classifier for 
subsequent cancer type prediction. 
E. Factor Number Selection 
Note that before factorization, a pre-defined number of factors 
𝐾 need to be selected. Typically, the number of factors K is 
chosen so that (𝑁 + 𝑀) × 𝐾 < 𝑁 × 𝑀 [23]. Selection of 𝐾 is 
critical because it determines the performance of the classifier. 
Numerous studies have presented different methods for factor 
number selection: The factor number 𝐾  can be determined 
based on different metrics composing of a cophenetic 
correlation coefficient [26, 41], variation of sum of squares [42],  
or maximum information reservation [43]. In our study, the 
most important feature for the classifier is the ability to 
distinguish the cancer types correctly. To achieve this goal, a 
numerical screening test was conducted to screen through the 
different number of factors for best prediction performance. 
The screened factor numbers ranged from 2 to 25. Multi-class 
prediction accuracy in each classification was obtained as a 
performance measurement. Five-fold cross-validation was 
conducted using multiple different factor numbers. Each 
experiment was replicated ten times with different initial seeds. 
Prediction accuracy, precision, recall, and f-measure were used 
as performance evaluation matrices. 
F. Evaluation 
To set up baselines for comparison, the mutation frequency and 
the collapsed scores in the selected genes were used as 
independent predictors to fit a SVM model and a penalized 
logistic regression model to predict cancer types. All somatic 
mutations were also used as predictive variables for cancer 
classification using the SVM model as well as the penalized 
logistical regression model. These methods were reported to 
have the best performances for cancer classification using 
somatic mutations [20]. All the studies were replicated ten times 
with different initial seeds and significance tests were 
performed. P-values were obtained for the evaluations.  
G. Pathway Study 
In the NMF formulation, the features matrix 𝐹 was obtained by 
multiplying matrix 𝐴𝑆𝑐𝑜𝑟𝑒  with matrix 𝑊, and it has size 𝑁 × 𝐾, 
with each 𝐾 columns representing the accumulative effect of 𝑀 
genes for the corresponding subject. To determine the 
association level of each factor with each cancer type, we 
studied each of the K factors’ coefficient in associating with the 
disease type. Elastic net regularization was used for this study.  
Elastic net regularization penalizes the size of the regression 
coefficients based on both L1 norm and L2 norm. The estimates 
from the elastic net methods are defined as:  
 
[?̂?, ?̂?0] = 𝑎𝑟𝑔𝑚𝑖𝑛𝛽(∑ (𝑦𝑖 − 𝛽
′𝐴𝑆𝑐𝑜𝑟𝑒 𝑊)
2 + 𝜆1 ∑ |𝛽𝑘|
𝐾
𝑘=1 +𝑖
𝜆2 ∑ 𝛽𝑘
2𝐾
𝑘=1 )                                                                            (3) 
 
𝑦𝑖  denotes the disease type, ?̂? = [?̂?1 , … , ?̂?𝑘] is the vector of 
regression coefficients for the K predictors.  
In this study, the regulation parameter λ was selected using 
cross-validation. ?̂? denotes the association level of each gene 
group to disease type. W is the weighted coefficient of each 
gene in the gene groups. We obtained each gene’s accumulative 
effect by multiplying matrix W with vector ?̂?. We used vector 
𝐸 to represent each gene’s association effect with each cancer 
type. Mathematically, let 
𝐸𝑖 = ∑ ?̂?𝑗 × 𝑊𝑖𝑗  
𝐾
𝑗=1                    (4) 
 
denote the 𝑖𝑡ℎ  gene’s association effect with the case and 
control. To note, the matrix 𝑊 was minmax normalized. Thus, 
we achieved a score that represents a gene’s association effect. 
To differentially discover pathways for a cancer type, subjects 
with the cancer type of interest were treated as cases and the rest 
subjects as controls. After fitting the regression model, we 
selected the factors corresponding to the largest ?̂?, and denote 
the factor as a cancer-specific factor. The variables in the factor, 
are different genes with coefficients. There is a potential that 
the genes with the largest coefficients are the same genes that 
cumulatively and linearly interact with each other to cause 
cancers. For each cancer, we repeated the experiment and 
selected the top 100 genes in each factor for enrichment analysis 
and presented the top 2 significant pathways (p < .05).  
. 
 
  
Figure 3: The accuracy of cancer type classification using different P-value cutoffs. (A) Sum of the count of mutations (B) Sum of the SIFT scores (C) Sum of the 
PP2 scores (D) Sum of the CADD scores. 
 
 
IV. EXPERIMENT RESULTS 
After collapsing mutations’ numbers and scores in each gene, a 
matrix 𝐴𝑠𝑐𝑜𝑟𝑒 was formed with the 2413 subjects as rows. Entry 
𝐴𝑖𝑗  denotes the 𝑗𝑡ℎ  gene’s collapsed score for the 𝑖𝑡ℎ  subject. 
For the gene preselection, we screened the 𝑝𝑣𝑎𝑙𝑢𝑒 of 0.05, 0.1, 
0.2, 0.5, and 1 as cutoffs. For each cutoff, prediction accuracy 
was used as performance measurements. The experiment was 
repeated using the Number (sum of the number of mutations), 
SIFT (sum of the sift scores), PP2 (sum of the PP2 score), and 
CADD (sum of CADD scores) matrices. Factor numbers ranged 
from 0 to 10 (Figure 3). Using a cutoff of 1 results in feature 
numbers 20 times more than using a cutoff of 0.05. However, 
the performance derived from the cutoff of 1 is not significantly 
different from the cutoff of 0.05. The 𝑝𝑣𝑎𝑙𝑢𝑒  equal 0.29 
comparing the two performances when using Number matrix. 
Balancing the number of features to be included for 
computation and accuracy, we selected the cutoff of 0.05 for 
gene preselections. Following gene preselection, 7,237, 9,483, 
8,787, and 8,219 genes were retained for subsequent analysis 
for the Number, SIFT, PP2, and CADD matrix respectively.  
We then compared these four matrices: Number, SIFT, PP2, 
and CADD. The number of factors K ranged from 2 to 25. This 
range is within the constraint of the rule (N+M)K<NM. For 
each factor number in this range, nsNMF was applied to the 
matrices, and the corresponding classifier was trained. The 
performances derived from the matrix Number outperformed 
the other matrices significantly (Figure 4). The precision, recall, 
and f-measures were also derived and similar patterns and 
trends were observed. Given the better performance, the matrix 
Number was used for subsequent analyses. Using Number 
matrix, the maximum accuracy is 78.4% (Standard Error of the 
Mean SEM=0.2%) when the factor number equaled 21. For 
performance accuracy, there is an inflection point when the 
cluster number increase from 10 to 11 (Figure 4). The accuracy 
becomes stable when factor number is larger than 10. To 
prevent the potential overfitting, we chose the factor of 10 for 
our analysis. With this factor number, the overall accuracy is 
77.1% (SEM=0.1%).  
 
 
  
Figure 4: The accuracy of cancer type predictions using different numbers of 
factor. The four plots were the accuracies derived from the matrices of Number, 
SIFT, PP2, and CADD scores.  
 
The performance of our proposed model (77.1%, SEM=0.1%) 
significantly outperformed the other four baselines (Figure 5). 
The P-value for Student’s t-test was 0.002 comparing our 
proposed model to the second-ranked model (73.9% 
(SEM=0.8%), which applies penalized logistical regression with 
the aggregated Number matrix. In the baselines, aggregating the 
mutations in a gene has improved the performance significantly 
too (p<0.01 in both comparisons). 
Figure 5 Comparison of our proposed model (nsNMF+SVM) with baselines. 
LR is penalized logistical regression. SVM is support vector machine. 
Aggregated is the matrix to sum variants together in the same gene. Mutation is 
the model that utilizes every single mutation as an input variable. 
 
In the regularized logistical regression study, we assessed each 
gene’s association effect with each cancer type. From the 
formula(4) , the association score is the sum of the feature 
weight multiplied by the weights of each gene in each feature. 
High scores indicate a significant role of a mutated gene in 
disease. We selected ten genes with the top association scores 
for breast cancer and found many of them have been previously 
implicated in breast cancer. MUC16 and RYR3 have been 
shown to play a role in tumorigenesis and have enriched 
expression in breast cancer patients [44-46]. Mutations in 
USH2A, and CTNNA have been identified to be associated with 
breast cancer risk in independent studies [47, 48] The nebulin 
protein family, HUWE1, and COL22A1 are also important 
genes that have been implicated in other cancers [49-51].These 
genes are summarized in Table 1.  
 
TABLE 1: THE GENE LIST WITH HIGHEST COEFFICIENTS FOR BREAST CANCER 
Gene 
Symbol 
Score Description 
CSMD3 0.63 CUB and Sushi multiple domains 3 
NEB 0.59 nebulin protein coding gene 
MUC16 0.56 mucin 16 
HUWE1 0.50 
HECT, UBA and WWE domain 
containing 1 
USH2A 0.41 usherin protein coding gene 
CTNNA2 0.40 
catenin (cadherin associated 
protein), alpha 2 
DNAH6 0.39 dynein, axonemal, heavy chain 6 
MYHAS 0.37 
myosin heavy chain gene antisense 
RNA 
RYR3 0.36 ryanodine receptor 3 
COL22A1 0.35 Collagen type XXII alpha 1 chain 
The top 100 genes associated with each cancer type were 
derived and analyzed in Metascape for pathway enrichment.  
Overall, we identified pathways that have been directly linked 
to cancer such as morphogenesis and ion transport pathways 
[52-54]. Furthermore, we also identified and confirmed some 
pathways known to be associated with specific cancers such as 
AKT signaling and glioblastoma (GBM) cancer [55, 56]. The 
top 2 significant pathways (p < .05) for each cancer type are 
illustrated in TABLE 2. 
TABLE 2: BIOLOGICAL PROCESSES MOST ASSOCIATED WITH EACH CANCER 
TYPE. 
GO Term Cancer 
Microtubule-based process BRCA 
Calcium ion transmembrane transport BRCA 
Focal adhesion GBM 
PI3K-Akt signaling pathway GBM 
Maintenance of protein location PRAD 
Cytoskeletal anchoring at plasma membrane PRAD 
Neuron projection morphogenesis LUSC 
Plasma membrane bounded cell projection 
morphogenesis 
LUSC 
V. DISCUSSION 
In this study, we have proposed a method to use somatic 
mutations to classify the cancer type and to derive the relevant 
genes and pathways. This is a new method to understand the 
somatic mutations. We used 8,198 tumors’ somatic mutational 
information to select 7,237 cancer-relevant genes. We then 
applied nsNMF and SVM to train a classifier to distinguish the 
2,413 tumors among four cancer types including Glioblastoma 
Multiforme (GBM), Breast invasive carcinoma (BRCA), Lung 
Squamous Cell Carcinoma (LUSC), and Prostate 
Adenocarcinoma (PRAD). Products of basis matrix and 
 coefficient matrix derived from nsNMF were both retained to 
construct the feature matrix. Subsequently, the constructed 
features were used as input variables to train the classifier. We 
compared functional scores using CADD, SIFT, and PP2, and 
counted mutation number and found that counted mutation 
number yielded the best performance (accuracy=77.1% with 
SEM=0.1%). Finally, regularized logistical regression was 
applied to study each gene’s association effect with cancer type. 
Using the associated features, we derived relevant genes and 
pathways for each cancer.  
When training the classifier, we used an alternative method by 
multiplying the matrix 𝐴𝑠𝑐𝑜𝑟𝑒  with matrix 𝑊  to obtain the 
feature matrix 𝐹. Thus, information from basis component W 
was retained, providing information about weights in each gene 
group. This information was then used as features to train the 
classifier. Another benefit of this alternative method is the 
resultant ease at the testing stage. With the trained 𝑊 matrix, 
we only need to left multiply the testing 𝐴𝑠𝑐𝑜𝑟𝑒 matrix in order 
to get the test feature matrix. In addition to improving cancer 
type classification, each gene’s association effect with the 
cancers was of interest and also studied. 
The development of high throughput sequencing technology 
has enabled the cataloging of large-scale mutation information. 
Traditionally, mutations derived from sequence data were 
examined as a single variable using the regression models [20, 
57]. Unfortunately, the large number of variables have limited 
the power of such studies. To reduce the number of variables, 
studies have proposed to aggregate mutations at the gene level 
as input for the regression model [39, 58, 59]. In other studies, 
mutations in a gene have also been proposed to be studied in a 
matrix as input for kernel test [60, 61]. In this study, we have 
proposed a new framework, which utilizes a regression model 
to preselect deleterious genes, nsNMF to decompose the matrix, 
SVM to train a classifier, and then penalized regression to 
derive relevant genes. In this framework, we have carefully 
tuned the parameters and models. We have also proved that this 
is an effective model to classify cancers, to derive relevant 
genes, and to study pathways.  
Given that the preselection process includes all our analyzed 
four cancers’ datasets, there is a potential of overfitting. We 
have used available data from all 18 cancers to reduce the 
potential overfitting issues. Nevertheless, our study still faces 
some limitations from overfitting and additional datasets will 
need to be included. 
VI. CONCLUSIONS 
To fully understand a disease, studying a full range of genes 
together is of critical importance. In addition, complex traits are 
modified by multiple genes and multiple mutations together 
[62]. Traditionally, NMF has been applied to study gene 
expression[26, 43]. In this study, we proposed using the somatic 
mutations for cancer classification. Furthermore, we proposed 
generating the feature matrix by integrating both the basis 
matrix W and the coefficient matrix H. Moreover, we developed 
a method to derive effect scores from the feature matrix. Using 
this method, we obtained the association score of each gene 
with a particular cancer type, which then enabled us to discover 
potential relevant pathways. The discovered effect scores have 
a high potential to help us better understand genetic 
pathophysiology behind cancer.  
In this study, we propose a novel strategy to study the difference 
of the genetic landscape of cancer. In the future, we will use 
tensor factorization to integrate known pathways to guide the 
grouping of mutational variants [63] and use external cohorts to 
validate the proposed model. Furthermore, this generic process 
only requires the input of somatic mutations and disease type of 
interest, without much domain specific knowledge. This 
strategy has the potential to be easily adapted and applied to 
other diseases as well. 
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